middle.news
Paradigm Surpasses Target in Phase 3 Osteoarthritis Trial Enrolment
9:11am on Monday 15th of June, 2026 AEST
•
Healthcare
Read Story
Paradigm Surpasses Target in Phase 3 Osteoarthritis Trial Enrolment
9:11am on Monday 15th of June, 2026 AEST
Key Points
Enrolment exceeds target with 538 participants
Phase 3 trial spans 65 sites across four countries
Interim analysis set for September 2026
Top-line results expected in Q1 2027
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Paradigm Biopharmaceuticals (ASX:PAR)
OPEN ARTICLE